Country Club Bank Sells 468 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Country Club Bank decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 22,411 shares of the medical research company’s stock after selling 468 shares during the period. Country Club Bank’s holdings in Thermo Fisher Scientific were worth $11,628,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Thermo Fisher Scientific by 18.3% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 56,387 shares of the medical research company’s stock valued at $28,502,000 after purchasing an additional 8,722 shares in the last quarter. Osprey Private Wealth LLC increased its position in shares of Thermo Fisher Scientific by 0.7% during the fourth quarter. Osprey Private Wealth LLC now owns 9,380 shares of the medical research company’s stock valued at $4,880,000 after acquiring an additional 65 shares in the last quarter. Sargent Investment Group LLC increased its position in shares of Thermo Fisher Scientific by 7.1% during the fourth quarter. Sargent Investment Group LLC now owns 711 shares of the medical research company’s stock valued at $395,000 after acquiring an additional 47 shares in the last quarter. Old North State Wealth Management LLC increased its position in shares of Thermo Fisher Scientific by 14.0% during the fourth quarter. Old North State Wealth Management LLC now owns 528 shares of the medical research company’s stock valued at $275,000 after acquiring an additional 65 shares in the last quarter. Finally, Ninety One SA PTY Ltd increased its position in shares of Thermo Fisher Scientific by 4.6% during the fourth quarter. Ninety One SA PTY Ltd now owns 14,922 shares of the medical research company’s stock valued at $7,763,000 after acquiring an additional 653 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Down 2.2 %

TMO opened at $580.63 on Wednesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. Thermo Fisher Scientific Inc. has a fifty-two week low of $493.30 and a fifty-two week high of $627.88. The firm’s fifty day moving average is $542.95 and its 200 day moving average is $571.55. The stock has a market cap of $222.09 billion, a price-to-earnings ratio of 35.13, a price-to-earnings-growth ratio of 4.06 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, beating analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.29 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were issued a $0.39 dividend. The ex-dividend date of this dividend was Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.44%.

Thermo Fisher Scientific announced that its Board of Directors has initiated a share repurchase plan on Friday, November 15th that authorizes the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to purchase up to 2% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on TMO shares. Robert W. Baird reduced their price target on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Evercore ISI reduced their price target on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. StockNews.com upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Barclays dropped their target price on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. Finally, TD Cowen raised their target price on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a report on Tuesday, October 22nd. Four investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $658.00.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $530.26, for a total value of $5,302,600.00. Following the sale, the chief executive officer now directly owns 111,192 shares in the company, valued at approximately $58,960,669.92. The trade was a 8.25 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.34% of the stock is currently owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.